<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="therapy applications of oncolytic viruses represent an attractive alternative for" exact="cancer" post="treatment. A broad range of oncolytic viruses, including adenoviruses,"/>
 <result pre="broad range of oncolytic viruses, including adenoviruses, adeno-associated viruses, alphaviruses," exact="herpes simplex" post="viruses, retroviruses, lentiviruses, rhabdoviruses, reoviruses, measles virus, Newcastle disease"/>
 <result pre="adeno-associated viruses, alphaviruses, herpes simplex viruses, retroviruses, lentiviruses, rhabdoviruses, reoviruses," exact="measles" post="virus, Newcastle disease virus, picornaviruses and poxviruses, have been"/>
 <result pre="the treatment of various diseases, including colon, head-and-neck, prostate and" exact="breast cancer" post="as well as squamous cell carcinoma and glioma. The"/>
 <result pre="treatment of various diseases, including colon, head-and-neck, prostate and breast" exact="cancer" post="as well as squamous cell carcinoma and glioma. The"/>
 <result pre="using viral vectors, with the focus on malignant melanoma. melanoma" exact="cancer" post="vector delivery gene therapy immunotherapy clinical trials 1. Introduction"/>
 <result pre="clinical trials 1. Introduction Melanoma, or malignant melanoma, represents a" exact="cancer" post="type that develops in melanocytes known as pigment-containing cells"/>
 <result pre="vector spread into neighboring cells, providing an interesting approach for" exact="cancer" post="therapy [32]. Immunization studies in experimental models have employed"/>
 <result pre="a wide range of viral vectors based on adenoviruses, alphaviruses," exact="herpes simplex" post="viruses, coxsackie viruses and vaccinia viruses, targeting cancer types"/>
 <result pre="alphaviruses, herpes simplex viruses, coxsackie viruses and vaccinia viruses, targeting" exact="cancer" post="types like glioblastoma, colon, cervix, and lung cancer as"/>
 <result pre="vaccinia viruses, targeting cancer types like glioblastoma, colon, cervix, and" exact="lung cancer" post="as well as melanoma [33,34]. The first virus-based melanoma"/>
 <result pre="viruses, targeting cancer types like glioblastoma, colon, cervix, and lung" exact="cancer" post="as well as melanoma [33,34]. The first virus-based melanoma"/>
 <result pre="a broad range of oncolytic viruses have been evaluated for" exact="cancer" post="gene therapy [107]. The specific targeting and killing of"/>
 <result pre="Type 1 The prototype drug for virotherapy is an attenuated" exact="herpes simplex" post="virus type 1 (HSV-1), which is engineered to express"/>
 <result pre="vector was more effective with respect to lysis in human" exact="breast cancer" post="cells than in a mixed culture of autologous hematopoietic"/>
 <result pre="was more effective with respect to lysis in human breast" exact="cancer" post="cells than in a mixed culture of autologous hematopoietic"/>
 <result pre="were chosen according to cutaneous and subcutaneous metastases from melanoma," exact="breast cancer" post="or squamous cell carcinoma of the head and neck"/>
 <result pre="chosen according to cutaneous and subcutaneous metastases from melanoma, breast" exact="cancer" post="or squamous cell carcinoma of the head and neck"/>
 <result pre="GM–CSF expression and HSV-antigen-associated necrosis were observed in melanoma, breast," exact="head and neck cancer." post="Six patients manifested flattening of injected/un-injected tumors, and in"/>
 <result pre="been used as gene therapy vectors for indications such as" exact="glioma" post="[77,78], and breast [81], gastric [82], liver [83], pancreatic"/>
 <result pre="cancers. One limitation of using retroviruses such as Moloney murine" exact="leukemia" post="virus (MoMLV) for gene therapy is the requirement of"/>
 <result pre="retroviruses have demonstrated potential for treating chronic diseases such as" exact="severe combined immunodeficiency" post="(SCID) in children [126], fewer studies have been conducted"/>
 <result pre="expressing GM–CSF and IL-4 showed high-level expression in cultured primary" exact="glioma" post="cells, which lasted for 14 days and could therefore"/>
 <result pre="suicide gene system demonstrated superior antitumor activity in a murine" exact="uveal melanoma" post="model [128]. In another study, a lentivirus vector expressing"/>
 <result pre="to lentivirus-based clinical trials, 30 children and adults with relapsed" exact="acute lymphoblastic leukemia" post="(ALL) were treated with a lentiviral vector-based chimeric antigen"/>
 <result pre="lentivirus-based clinical trials, 30 children and adults with relapsed acute" exact="lymphoblastic leukemia" post="(ALL) were treated with a lentiviral vector-based chimeric antigen"/>
 <result pre="clinical trials, 30 children and adults with relapsed acute lymphoblastic" exact="leukemia" post="(ALL) were treated with a lentiviral vector-based chimeric antigen"/>
 <result pre="in the antigen-positive tumor cells, showing the potential of lentivirus-based" exact="cancer" post="immunotherapy. The success of CAR-T based lentivirus therapy for"/>
 <result pre="cancers. It was confirmed that reoviruses can kill six human" exact="breast cancer" post="cell lines (SK-BR-3, KPL4, MDA-MB-453, CRL1500, MCFT and MDA-MB-231)"/>
 <result pre="It was confirmed that reoviruses can kill six human breast" exact="cancer" post="cell lines (SK-BR-3, KPL4, MDA-MB-453, CRL1500, MCFT and MDA-MB-231)"/>
 <result pre="MDA-MB-453, CRL1500, MCFT and MDA-MB-231) expressing HER-2, but not the" exact="breast cancer" post="cell line Hs578Bst, which did not show HER-2 expression"/>
 <result pre="CRL1500, MCFT and MDA-MB-231) expressing HER-2, but not the breast" exact="cancer" post="cell line Hs578Bst, which did not show HER-2 expression"/>
 <result pre="be implemented for the treatment of a wide range of" exact="cancer" post="types. 3.3.2. Clinical Trials of Reoviruses in Melanoma Treatment"/>
 <result pre="has been conducted for solid tumors including soft-tissue sarcomas, melanoma," exact="breast cancer" post="and head and neck cancer [145]. One study included"/>
 <result pre="been conducted for solid tumors including soft-tissue sarcomas, melanoma, breast" exact="cancer" post="and head and neck cancer [145]. One study included"/>
 <result pre="for solid tumors including soft-tissue sarcomas, melanoma, breast cancer and" exact="head and neck cancer" post="[145]. One study included 18 patients and was mainly"/>
 <result pre="including soft-tissue sarcomas, melanoma, breast cancer and head and neck" exact="cancer" post="[145]. One study included 18 patients and was mainly"/>
 <result pre="ICAM-1 [156]. The discovery of CVA21 and its lysis of" exact="cancer" post="cells was mainly achieved through research conducted on ICAM-1"/>
 <result pre="conducted on ICAM-1 and DAF receptors, and comparisons between various" exact="cancer" post="cell lines and nonmalignant tissues. It has also been"/>
 <result pre="It has also been shown for melanoma as well as" exact="multiple myeloma," post="malignant glioma, breast, colon, endometrial and pancreatic cancer cell"/>
 <result pre="well as multiple myeloma, malignant glioma, breast, colon, endometrial and" exact="pancreatic cancer" post="cell lines [157,158]. 3.4.1. Preclinical Studies with CVA21 Overexpression"/>
 <result pre="as multiple myeloma, malignant glioma, breast, colon, endometrial and pancreatic" exact="cancer" post="cell lines [157,158]. 3.4.1. Preclinical Studies with CVA21 Overexpression"/>
 <result pre="The specific replication in tumor cells makes NDV attractive for" exact="cancer" post="therapy [89]. 3.5.1. Preclinical Studies with NDV Regarding preclinical"/>
 <result pre="strain 73-T caused complex tumor regression in athymic mice containing" exact="fibrosarcoma" post="xenografts [169]. Even a single intratumoral administration caused complete"/>
 <result pre="complete and long-lasting remission. The NDV LaSota strain showed superior" exact="suppression" post="of tumor growth in comparison to a recombinant rNDV"/>
 <result pre="tumor development [83]. Prolonged survival was reported in mice carrying" exact="hepatocellular carcinoma" post="(HCCs) and melanoma cells, which received the rNDV-IL-2-TRAIl vector"/>
 <result pre="is toxic in birds, and the neurotoxicity of VSV (Vesicular" exact="stomatitis" post="virus), a hybrid vector was engineered, where the VSV"/>
 <result pre="NDV NDV has been applied in various clinical trials for" exact="cancer" post="therapy. A long-term survival in phase II trials of"/>
 <result pre="cancers was observed [171]. Three hundred and thirty-five individuals with" exact="colorectal cancer" post="were immunized with NDV vectors in a phase III"/>
 <result pre="was observed [171]. Three hundred and thirty-five individuals with colorectal" exact="cancer" post="were immunized with NDV vectors in a phase III"/>
 <result pre="Semliki Forest virus (SFV), Sindbis virus (SIN) and Venezuelan equine" exact="encephalitis" post="virus (VEE) [173,174,175]. RNA replicons as well as recombinant"/>
 <result pre="alphavirus particles and DNA/RNA layered plasmids have been applied for" exact="cancer" post="therapy. In one study, mice were immunized with SFV-LacZ"/>
 <result pre="Tumor targeting represents one important consideration when using alphaviruses for" exact="cancer" post="treatment. It has been reported that SIN particles possess"/>
 <result pre="systemic delivery [177]. Alphavirus vectors have shown promising potential in" exact="cancer" post="treatment because of easy and fast production of high-titer"/>
 <result pre="study, an SFV DNA replicon vector carrying the bovine viral" exact="diarrhea" post="virus (BVDV) p80 (NS3) was administered into the quadricep"/>
 <result pre="cells. In another approach, a SIN RNA replicon expressing the" exact="rabies" post="virus glycoprotein gene was applied for immunization of mice"/>
 <result pre="10 µg of SIN-Rab-G RNA [183]. Compared to a conventional" exact="rabies" post="DNA vaccine and the Rabipur commercial cell culture vaccine,"/>
 <result pre="vaccine, similar cellular and humoral immune responses and protection against" exact="rabies" post="were obtained. 3.6.2. Clinical Trials with Alphaviruses In attempts"/>
 <result pre="Additional clinical trials have been conducted with alphaviruses for various" exact="cancer" post="types and viral diseases, demonstrating good safety of the"/>
 <result pre="several preclinical tumor models and clinical studies. They have provided" exact="suppression" post="of tumor growth and regression as well as increased"/>
 <result pre="Inst.19989088990510.1093/jnci/90.12.8899637138 27.BrownS.B.BrownE.A.WalkerI.The present and future role of photodynamic therapy in" exact="cancer" post="treatmentLancet Oncol.2004549750810.1016/S1470-2045(04)01529-315288239 28.LongoJ.MuehlmannL.Almeida-SantosM.AzevedoR.Preventing metastasis by targeting lymphatic vessels with"/>
 <result pre="metastatic melanoma cellsJ. Photochem. Photobiol. B Biol.2017166182710.1016/j.jphotobiol.2016.11.004 32.LundstromK.Oncolytic alphaviruses in" exact="cancer" post="immunotherapyVaccines (Basel)20175910.3390/vaccines5020009 33.StoneD.Novel viral vector systems for gene therapyViruses201021002100710.3390/v204100221994667"/>
 <result pre="and decreased toxicityNat. Genet.19981818018310.1038/ng0298-1809462752 38.WangF.WangZ.TianH.QiM.ZhaiZ.LiS.LiR.ZhangH.WangW.FuS.et al.Biodistribution and safety assessment of" exact="bladder cancer" post="specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model"/>
 <result pre="decreased toxicityNat. Genet.19981818018310.1038/ng0298-1809462752 38.WangF.WangZ.TianH.QiM.ZhaiZ.LiS.LiR.ZhangH.WangW.FuS.et al.Biodistribution and safety assessment of bladder" exact="cancer" post="specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model"/>
 <result pre="immunity by sunitinib enhances oncolytic virotherapyMol. Ther.2013211749175710.1038/mt.2013.11223732991 40.ShapiraS.ShapiraA.KazanovD.HevroniG.KrausS.ArberN.Selective eradication of" exact="cancer" post="cells by delivery of adenovirus-based toxinsOncotarget201783858110.18632/oncotarget.1693428445136 41.Sato-DahlmanM.MiuraY.HuangJ.L.HajeriP.JacobsenK.DavydovaJ.YamamotoM.CD133-targeted oncolytic adenovirus"/>
 <result pre="44.ChenJ.GaoP.YuanS.LiR.NiA.ChuL.DingL.SunY.LiuX.-Y.DuanY.Oncolytic adenovirus complexes coated with lipids and calcium phosphate for" exact="cancer" post="gene therapyACS Nano201610115481156010.1021/acsnano.6b0618227977128 45.LiuZ.YangY.ZhangX.WangH.XuW.WangH.XiaoF.BaiZ.YaoH.MaX.et al.An oncolytic adenovirus encoding decorin"/>
 <result pre="and interleukin-24 on hepatocellular carcinomaTumour Biol.2013343027303410.1007/s13277-013-0867-z23907578 53.SuH.ChangJ.C.XuS.M.KanY.W.Selective killing of AFP-positive" exact="hepatocellular carcinoma" post="cells by adeno-associated virus transfer of the herpes simplex"/>
 <result pre="AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the" exact="herpes simplex" post="virus thymidine kinase geneHum. Gene Ther.1996746347010.1089/hum.1996.7.4-4638800740 54.LuL.LuoS.-T.ShiH.S.LiM.ZhangH.L.HeS.S.LiuY.PanY.YangL.AAV2-mediated gene transfer"/>
 <result pre="geneHum. Gene Ther.1996746347010.1089/hum.1996.7.4-4638800740 54.LuL.LuoS.-T.ShiH.S.LiM.ZhangH.L.HeS.S.LiuY.PanY.YangL.AAV2-mediated gene transfer of VEGF-Trap with potent" exact="suppression" post="of primary breast tumor growth and spontaneous pulmonary metastases"/>
 <result pre="RNA for androgen receptor gene silencing induces tumor eradication of" exact="prostate cancer" post="xenografts in nude mice: A preclinical studyInt. J. Cancer201012676477410.1002/ijc.2477819642108"/>
 <result pre="for androgen receptor gene silencing induces tumor eradication of prostate" exact="cancer" post="xenografts in nude mice: A preclinical studyInt. J. Cancer201012676477410.1002/ijc.2477819642108"/>
 <result pre="Cancer201012676477410.1002/ijc.2477819642108 56.ShihC.-S.LaurieN.HolzmacherJ.SpenceY.NathwaniA.C.DavidoffA.M.DyerM.A.AAV-mediated local delivery of interferon-beta for the treatment of" exact="retinoblastoma" post="in preclinical modelsNeuromol. Med.200911435210.1007/s12017-009-8059-019306089 57.HeikkiläJ.E.Vähä-KoskelaM.J.RuotsalainenJ.J.MartikainenM.W.StanfordM.M.McCartJ.A.BellJ.C.HinkkanenA.E.Intravenously administered alphavirus vector VA7"/>
 <result pre="modelsNeuromol. Med.200911435210.1007/s12017-009-8059-019306089 57.HeikkiläJ.E.Vähä-KoskelaM.J.RuotsalainenJ.J.MartikainenM.W.StanfordM.M.McCartJ.A.BellJ.C.HinkkanenA.E.Intravenously administered alphavirus vector VA7 eradicates orthotopic human" exact="glioma" post="xenografts in nude micePLoS ONE20105e860310.1371/journal.pone.000860320066051 58.YingH.ZaksT.Z.WangR.-F.IrvineK.R.KammulaU.S.MarincolaF.M.LeitnerW.W.RestifoN.P.Cancer therapy using a"/>
 <result pre="therapy using a self-replicating RNA vaccineNat. Med.1999582382710.1038/1054810395329 59.MurphyA.-M.Morris-DownesM.M.SheahanB.J.AtkinsG.J.Inhibition of human" exact="lung carcinoma" post="cell growth by apoptosis induction using Semliki Forest virus"/>
 <result pre="xenografts in severe combined immunodeficient miceCancer Res.2006667185719410.1158/0008-5472.CAN-05-221416849565 61.MäättäA.M.LiimatainenT.WahlforsT.WirthT.Vähä-KoskelaM.JanssonL.ValonenP.HäkkinenK.RautsiO.PellinenR.et al.Evaluation of" exact="cancer" post="virotherapy with attenuated replicative Semliki forest virus in different"/>
 <result pre="Gene TherapyAvailable online: http://www.eurekaselect.com/61113/article(accessed on 12 November 2019) 66.HolmesK.D.CassamA.K.ChanB.PetersA.A.WeaverL.C.DekabanG.A.A multi-mutant" exact="herpes simplex" post="virus vector has minimal cytotoxic effects on the distribution"/>
 <result pre="virus to target gliomaOncotarget20167286582866910.18632/oncotarget.863727070093 68.EsakiS.RabkinS.D.MartuzaR.L.WakimotoH.Transient fasting enhances replication of oncolytic" exact="herpes simplex" post="virus in glioblastomaAm. J. Cancer Res.2016630031127186404 69.YinL.ZhaoC.HanJ.LiZ.ZhenY.XiaoR.XuZ.SunY.Antitumor effects of"/>
 <result pre="virus in glioblastomaAm. J. Cancer Res.2016630031127186404 69.YinL.ZhaoC.HanJ.LiZ.ZhenY.XiaoR.XuZ.SunY.Antitumor effects of oncolytic" exact="herpes simplex" post="virus type 2 against colorectal cancer in vitro and"/>
 <result pre="69.YinL.ZhaoC.HanJ.LiZ.ZhenY.XiaoR.XuZ.SunY.Antitumor effects of oncolytic herpes simplex virus type 2 against" exact="colorectal cancer" post="in vitro and in vivoTher. Clin. Risk Manag.20171311713010.2147/TCRM.S12857528223815 70.LiH.NakashimaH.DeckleverT.D.NaceR.A.RussellS.J.HSV-NIS,"/>
 <result pre="effects of oncolytic herpes simplex virus type 2 against colorectal" exact="cancer" post="in vitro and in vivoTher. Clin. Risk Manag.20171311713010.2147/TCRM.S12857528223815 70.LiH.NakashimaH.DeckleverT.D.NaceR.A.RussellS.J.HSV-NIS,"/>
 <result pre="vitro and in vivoTher. Clin. Risk Manag.20171311713010.2147/TCRM.S12857528223815 70.LiH.NakashimaH.DeckleverT.D.NaceR.A.RussellS.J.HSV-NIS, an oncolytic" exact="herpes simplex" post="virus type 1 encoding human sodium iodide symporter for"/>
 <result pre="virus type 1 encoding human sodium iodide symporter for preclinical" exact="prostate cancer" post="radiovirotherapyCancer Gene Ther.20132047848510.1038/cgt.2013.4323868101 71.ChenC.-Y.WangP.-Y.HutzenB.SpragueL.SwainH.M.LoveJ.K.StanekJ.R.BoonL.ConnerJ.CripeT.P.Cooperation of oncolytic herpes virotherapy and"/>
 <result pre="type 1 encoding human sodium iodide symporter for preclinical prostate" exact="cancer" post="radiovirotherapyCancer Gene Ther.20132047848510.1038/cgt.2013.4323868101 71.ChenC.-Y.WangP.-Y.HutzenB.SpragueL.SwainH.M.LoveJ.K.StanekJ.R.BoonL.ConnerJ.CripeT.P.Cooperation of oncolytic herpes virotherapy and"/>
 <result pre="71.ChenC.-Y.WangP.-Y.HutzenB.SpragueL.SwainH.M.LoveJ.K.StanekJ.R.BoonL.ConnerJ.CripeT.P.Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine" exact="rhabdomyosarcoma" post="modelsSci. Rep.20177239610.1038/s41598-017-02503-828539588 72.MeshiiN.TakahashiG.OkunagaS.HamadaM.IwaiS.TakasuA.OgawaY.YuraY.Enhancement of systemic tumor immunity for squamous"/>
 <result pre="tumor immunity for squamous cell carcinoma cells by an oncolytic" exact="herpes simplex" post="virusCancer Gene Ther.20132049349810.1038/cgt.2013.4523887644 73.GalanisE.MarkovicS.N.SumanV.J.NuovoG.J.VileR.G.KottkeT.J.NevalaW.K.ThompsonM.A.LewisJ.E.RumillaK.M.et al.Phase II trial of intravenous"/>
 <result pre="Strain) in patients with metastatic melanomaMol. Ther.201220199810.1038/mt.2012.14622871663 74.SchambachA.MorganM.Retroviral vectors for" exact="cancer" post="gene therapyRecent Results Cancer Res.2016209173528101685 75.HuW.S.PathakV.K.Design of retroviral vectors"/>
 <result pre="vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse" exact="glioma" post="modelHum. Gene Ther.201526829310.1089/hum.2014.10025419577 78.WakimotoH.YoshidaY.AyoyagiM.HirakawaK.HamadaH.Efficient retrovirus-mediated cytokine-gene transduction of primary-cultured"/>
 <result pre="modelHum. Gene Ther.201526829310.1089/hum.2014.10025419577 78.WakimotoH.YoshidaY.AyoyagiM.HirakawaK.HamadaH.Efficient retrovirus-mediated cytokine-gene transduction of primary-cultured human" exact="glioma" post="cells for tumor vaccination therapyJpn. J. Cancer Res.19978829630510.1111/j.1349-7006.1997.tb00381.x9140115 79.VignaE.NaldiniL.Lentiviral"/>
 <result pre="therapeuticsNat. Med.20017334010.1038/8332411135613 81.WangY.JinT.DaiX.XuI.Lentivirus-mediated knockdown of CEP55 suppressed cell proliferation of" exact="breast cancer" post="cellsBiosc. Trends201610677310.5582/bst.2016.01010 82.LiR.YangH.-Q.XiH.-L.FengS.QinR.-H.Inhibition of CDH17 gene expression via RNA"/>
 <result pre="Med.20017334010.1038/8332411135613 81.WangY.JinT.DaiX.XuI.Lentivirus-mediated knockdown of CEP55 suppressed cell proliferation of breast" exact="cancer" post="cellsBiosc. Trends201610677310.5582/bst.2016.01010 82.LiR.YangH.-Q.XiH.-L.FengS.QinR.-H.Inhibition of CDH17 gene expression via RNA"/>
 <result pre="RNA interference reduces proliferation and apoptosis of human MKN28 gastric" exact="cancer" post="cellsInt. J. Oncol.201750152210.3892/ijo.2016.378327909714 83.PanZ.Y.YangY.PanH.ZhangJ.LiuH.YangY.HaungG.YinL.HuangJ.ZhouW.P.Lentivirus-mediated TDP52L2 depletion inhibits the proliferation"/>
 <result pre="cellsInt. J. Oncol.201750152210.3892/ijo.2016.378327909714 83.PanZ.Y.YangY.PanH.ZhangJ.LiuH.YangY.HaungG.YinL.HuangJ.ZhouW.P.Lentivirus-mediated TDP52L2 depletion inhibits the proliferation of" exact="liver cancer" post="cells in vitroInt. J. Clin. Exp. Med.20158233241 84.RavetE.LulkaH.GrossF.CasteillaL.BuscailL.CordelierP.Using lentiviral"/>
 <result pre="J. Oncol.201750152210.3892/ijo.2016.378327909714 83.PanZ.Y.YangY.PanH.ZhangJ.LiuH.YangY.HaungG.YinL.HuangJ.ZhouW.P.Lentivirus-mediated TDP52L2 depletion inhibits the proliferation of liver" exact="cancer" post="cells in vitroInt. J. Clin. Exp. Med.20158233241 84.RavetE.LulkaH.GrossF.CasteillaL.BuscailL.CordelierP.Using lentiviral"/>
 <result pre="vitroInt. J. Clin. Exp. Med.20158233241 84.RavetE.LulkaH.GrossF.CasteillaL.BuscailL.CordelierP.Using lentiviral vectors for efficient" exact="pancreatic cancer" post="gene therapyCancer Gene Ther.20101731532410.1038/cgt.2009.7919911032 85.TianL.LiuJ.XiaG.-H.ChenB.-A.RNAi-mediated knockdown of MCM7 gene"/>
 <result pre="J. Clin. Exp. Med.20158233241 84.RavetE.LulkaH.GrossF.CasteillaL.BuscailL.CordelierP.Using lentiviral vectors for efficient pancreatic" exact="cancer" post="gene therapyCancer Gene Ther.20101731532410.1038/cgt.2009.7919911032 85.TianL.LiuJ.XiaG.-H.ChenB.-A.RNAi-mediated knockdown of MCM7 gene"/>
 <result pre="therapeutic potential for leukemiaMed. Oncol.2017342110.1007/s12032-016-0878-x28058629 86.OsakadaF.CallawayE.M.Design and generation of recombinant" exact="rabies" post="virus vectorsNat. Protoc.201381583160110.1038/nprot.2013.09423887178 87.Measles McDonaldC.J.ErlichmanC.IngleJ.N.RosalesG.A.AllenC.GreinerS.M.HarveyM.E.ZollmanP.J.RussellS.J.GalanisE.A measles virus vaccine strain"/>
 <result pre="and generation of recombinant rabies virus vectorsNat. Protoc.201381583160110.1038/nprot.2013.09423887178 87.Measles McDonaldC.J.ErlichmanC.IngleJ.N.RosalesG.A.AllenC.GreinerS.M.HarveyM.E.ZollmanP.J.RussellS.J.GalanisE.A" exact="measles" post="virus vaccine strain derivative as a novel oncolytic agent"/>
 <result pre="agent against breast cancerBreast Cancer Res. Treat.20069917718410.1007/s10549-006-9200-516642271 88.LampeJ.BossowS.WeilandT.SmirnowI.LehmannR.NeubertW.BitzerM.LauerU.M.An armed oncolytic" exact="measles" post="vaccine virus eliminates human hepatoma cells independently of apoptosisGene"/>
 <result pre="independently of apoptosisGene Ther.2013201033104110.1038/gt.2013.2823719065 89.CsataryL.K.MossR.W.BeuthJ.TöröcsikB.SzeberenyiJ.BakacsT.Beneficial treatment of patients with advanced" exact="cancer" post="using a Newcastle disease virus vaccine (MTH-68/H)Anticancer Res.19991963563810216468 90.LundstromK.New"/>
 <result pre="human enteroviruses against human prostate cancerProstate20086857758710.1002/pros.2074118288643 100.KwakH.HörigH.KaufmanH.L.Poxviruses as vectors for" exact="cancer" post="immunotherapyCurr. Opin. Drug Discov. Devel.20036161168 101.ZehH.J.BartlettD.L.Development of a replication-selective,"/>
 <result pre="CEA and MUC1 in carcinomaExpert Opin. Biol. Ther.2007754355410.1517/14712598.7.4.54317373905 104.MansfieldD.C.KyulaJ.N.RosenfelderN.Chao-ChuJ.Kramer-MarekG.KhanA.A.RoulstoneV.McLaughlinM.MelcherA.A.VileR.G.et al.Oncolytic" exact="vaccinia virus" post="as a vector for therapeutic sodium iodide symporter gene"/>
 <result pre="immunotherapyExpert Rev. Anticancer Ther.200881581158810.1586/14737140.8.10.158118925850 110.ChioccaE.RabkinS.Oncolytic viruses and their application to" exact="cancer" post="immunotherapyCancer Immunol. Res.2014229530010.1158/2326-6066.CIR-14-001524764576 111.AurelianL.Oncolytic viruses as immunotherapy: Progress and"/>
 <result pre="Genesis to genetic engineeringMol. Ther.20071565165910.1038/sj.mt.630010817299401 113.JhawarS.R.ThandoniA.BommareddyP.K.HassanS.KohlhappF.J.GoyalS.SchenkelJ.M.SilkA.W.ZlozaA.Oncolytic viruses—Natural and genetically engineered" exact="cancer" post="immunotherapiesFront. Oncol.2017710.3389/fonc.2017.00202 114.BommareddyP.K.PatelA.HossainS.KaufmanH.L.Talimogene laherparepvec (T-VEC) and other oncolytic viruses"/>
 <result pre="123.HuJ.C.C.CoffinR.S.DavisC.J.GrahamN.J.GrovesN.GuestP.J.HarringtonK.J.JamesN.D.LoveC.A.McNeishI.et al.A phase I study of OncoVEXGM-CSF, a second-generation oncolytic" exact="herpes simplex" post="virus expressing granulocyte macrophage colony-stimulating factorClin. Cancer Res.2006126737674710.1158/1078-0432.CCR-06-075917121894 124.SenzerN.N.KaufmanH.L.AmatrudaT.NemunaitisM.ReidT.DanielsG.GonzalezR.GlaspyJ.WhitmanE.HarringtonK.et"/>
 <result pre="vectorsCurr. Gene Ther.20022455510.2174/156652302334823712108973 126.Cavazzana-CalvoM.Hacein-BeyS.De Saint BasileG.GrossF.YvonE.NusbaumP.SelzF.HueC.CertainS.CasanovaJ.-L.et al.Gene therapy of human" exact="severe combined immunodeficiency" post="(SCID)-X1 diseaseScience200028866967210.1126/science.288.5466.66910784449 127.BastideC.MarocN.BladouF.HassounJ.MaitlandN.MannoniP.BagnisC.Expression of a model gene in prostate"/>
 <result pre="combined immunodeficiency (SCID)-X1 diseaseScience200028866967210.1126/science.288.5466.66910784449 127.BastideC.MarocN.BladouF.HassounJ.MaitlandN.MannoniP.BagnisC.Expression of a model gene in" exact="prostate cancer" post="cells lentivirally transduced in vitro and in vivoProstate Cancer"/>
 <result pre="immunodeficiency (SCID)-X1 diseaseScience200028866967210.1126/science.288.5466.66910784449 127.BastideC.MarocN.BladouF.HassounJ.MaitlandN.MannoniP.BagnisC.Expression of a model gene in prostate" exact="cancer" post="cells lentivirally transduced in vitro and in vivoProstate Cancer"/>
 <result pre="VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine" exact="uveal melanoma" post="modelExp. Eye Res.201817214415110.1016/j.exer.2018.04.00929660328 129.LeiY.ZhangB.ZhangY.ZhaoY.SunJ.ZhangX.YangS.Lentivirus-mediated downregulation of MAT2B inhibits cell"/>
 <result pre="133.SimonB.HarrerD.C.ThirionC.Schuler-ThurnerB.SchulerG.UsluU.Enhancing lentiviral transduction to generate melanoma-specific human T cells for" exact="cancer" post="immunotherapyJ. Immunol. Methods2019472556410.1016/j.jim.2019.06.01531207210 134.MilotouA.N.PapadopoulouL.C.CAR T-cell therapy: A new era"/>
 <result pre="immunotherapyJ. Immunol. Methods2019472556410.1016/j.jim.2019.06.01531207210 134.MilotouA.N.PapadopoulouL.C.CAR T-cell therapy: A new era in" exact="cancer" post="immunotherapyCurr. Pharm. Biotechnol.20181951810.2174/138920101966618041809552629667553 135.SimonB.UsluU.CAR-T cell therapy in melanoma: A"/>
 <result pre="with activated Ras pathwayScience19982821332133410.1126/science.282.5392.13329812900 142.HataY.EtohT.InomataM.ShiraishiN.NishizonoA.KitanoS.Efficacy of oncolytic reovirus against human" exact="breast cancer" post="cellsOncol. Rep.2008191395139818497942 143.TwiggerK.VidalL.WhiteC.L.BonoJ.S.D.BhideS.CoffeyM.ThompsonB.VileR.G.HeinemannL.PandhaH.S.et al.Enhanced in vitro and in vivo"/>
 <result pre="activated Ras pathwayScience19982821332133410.1126/science.282.5392.13329812900 142.HataY.EtohT.InomataM.ShiraishiN.NishizonoA.KitanoS.Efficacy of oncolytic reovirus against human breast" exact="cancer" post="cellsOncol. Rep.2008191395139818497942 143.TwiggerK.VidalL.WhiteC.L.BonoJ.S.D.BhideS.CoffeyM.ThompsonB.VileR.G.HeinemannL.PandhaH.S.et al.Enhanced in vitro and in vivo"/>
 <result pre="in patients with advanced solid tumorsInvestig. New Drugs20133169670610.1007/s10637-012-9865-z22886613 145.ClementsD.HelsonE.GujarS.A.LeeP.W.Reovirus in" exact="cancer" post="therapy: An evidence-based reviewOncolytic Virother.20143698227512664 146.ForsythP.RoldánG.GeorgeD.WallaceC.PalmerC.A.MorrisD.CairncrossG.MatthewsM.V.MarkertJ.GillespieY.et al.A phase I"/>
 <result pre="increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7" exact="breast cancer" post="cells and jurkat cellsScand. J. Immunol.200051737810.1046/j.1365-3083.2000.00653.x10632979 158.AuG.G.LinczL.F.EnnoA.ShafrenD.R.Oncolytic Coxsackievirus A21"/>
 <result pre="the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast" exact="cancer" post="cells and jurkat cellsScand. J. Immunol.200051737810.1046/j.1365-3083.2000.00653.x10632979 158.AuG.G.LinczL.F.EnnoA.ShafrenD.R.Oncolytic Coxsackievirus A21"/>
 <result pre="specific immunization with Newcastle disease virus modified tumor cells in" exact="colorectal cancer" post="patients following resection of liver metastasis: Results of a"/>
 <result pre="immunization with Newcastle disease virus modified tumor cells in colorectal" exact="cancer" post="patients following resection of liver metastasis: Results of a"/>
 <result pre="gene expression in animal cellsScience19892431188119110.1126/science.29226072922607 175.DavisN.L.WillisL.V.SmithJ.F.JohnstonR.E.In vitro synthesis of infectious" exact="venezuelan equine encephalitis" post="virus RNA from a cDNA clone: Analysis of a"/>
 <result pre="in animal cellsScience19892431188119110.1126/science.29226072922607 175.DavisN.L.WillisL.V.SmithJ.F.JohnstonR.E.In vitro synthesis of infectious venezuelan equine" exact="encephalitis" post="virus RNA from a cDNA clone: Analysis of a"/>
 <result pre="murine model for cervical cancerGene Ther.2007141695170410.1038/sj.gt.330303617928874 180.HariharanM.J.DriverD.A.TownsendK.BrummD.PoloJ.M.BelliB.A.CattonD.J.HsuD.MittelstaedtD.McCormackJ.E.et al.DNA immunization against" exact="herpes simplex" post="virus: Enhanced efficacy using a sindbis virus-based vectorJ. Virol.19987295095810.1128/JVI.72.2.950-958.19989444987"/>
 <result pre="vectorJ. Virol.19987295095810.1128/JVI.72.2.950-958.19989444987 181.ReddyJ.R.KwangJ.VarthakaviV.LechtenbergK.F.MinochaH.C.Semliki forest virus vector carrying the bovine viral" exact="diarrhea" post="virus NS3 (p80) cDNA induced immune responses in mice"/>
 <result pre="ONE201510e011704210.1371/journal.pone.011704225643354 183.SaxenaS.SonwaneA.A.DahiyaS.S.PatelC.L.SainiM.RaiA.GuptaP.K.Induction of immune responses and protection in mice against" exact="rabies" post="using a self-replicating RNA vaccine encoding rabies virus glycoproteinVet."/>
 <result pre="in mice against rabies using a self-replicating RNA vaccine encoding" exact="rabies" post="virus glycoproteinVet. Microbiol.2009136364410.1016/j.vetmic.2008.10.03019081687 biomedicines-08-00060-t001_Table 1Table 1 Viruses and their"/>
</results>
